Truist lowered the firm’s price target on Hims & Hers to $37 from $48 and keeps a Hold rating on the shares. The firm’s intra-quarter Truist Card Data suggests that the company’s GLP-1 related revenues may step up in the quarter, with a further modest increase in Q4, largely driven by realizing deferred revenue, though its estimated revenue mix for the second half makes Truist less constructive about the y/y growth in 2026, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Insider Moves: United, Devon, Datadog, Hims & Hers, fuboTV
- Here’s Why Wall Street Is Cautious on Hims & Hers Health Stock (HIMS)
- Hims & Hers calls Bloomberg story on FTC probe ‘rehashed’
- Hims & Hers probed by FTC over cancellation practices complaints, Bloomberg says
- Hims & Hers Stock (HIMS) Tanks on Reports of Year-Long FTC Investigation